A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

This study is being done to see if adding GLIADEL to the site where the tumor was removed works as well as just having the tumor removed with radiation treatment done within six weeks after the surgery to keep the cancer from coming back.

Trial Details

NCT ID
NCT04222062
Phase
PHASE2
Sponsor
University of Nebraska
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Carmustine 7.7Mg Wafer
Locations (sample)
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Omaha, Nebraska, United States|41.25626,-95.94043

Key Eligibility Criteria

  • Age 18 years or older (in states with 18 as age of majority); Age 19 years or older in Nebraska (age of majority)
  • Recursive partitioning analysis (RPA) class I, II or III with a Karnofsky Performance Status (KPS) of \>/ 60
  • Known or suspected primary solid cancer with metastatic brain tumor(s) - up to four in number and up to 4 cm in size with surgical resection planne…
  • Laboratory values adequate for patient to undergo surgery safely as determined by the attending neurosurgeon (transfusion permitted to reach goals)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →